Pharmaceutical Composition for Cancer Treatment

Abstract

The disclosure provides a pharmaceutical composition with a polypeptide that binds to a peptide produced by cDNA of GenBank ACC No. NM_005201.3 or NM_007720.2, and methods of use thereof.

1 . A method of treating cancer in a subject in need thereof, comprising
 administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an antibody against CCR8.   
     
     
         2 . (canceled) 
     
     
         3 . The method according to  claim 1 , wherein the cancer is breast cancer. 
     
     
         4 . The method according to  claim 1 , wherein the cancer is colorectal cancer. 
     
     
         5 . The method according to  claim 1 , wherein the cancer is kidney cancer. 
     
     
         6 . The method according  claim 1 , wherein the cancer is sarcoma. 
     
     
         7 . The method according to  claim 1 , wherein the cancer is lung cancer. 
     
     
         8 - 10 . (canceled) 
     
     
         11 . The method according to  claim 1 , wherein the antibody is an IgG antibody. 
     
     
         12 . The method according to  claim 1 , wherein the antibody against CCR8 is a CCR8-neutralizing antibody. 
     
     
         13 . The method according to  claim 1 , wherein the therapeutically effective amount is at a dose of 5 mg to 5000 mg. 
     
     
         14 . The method according to  claim 1 , wherein the therapeutically effective amount is at a dose of 10 mg to 500 mg. 
     
     
         15 . The method according to  claim 1 , wherein the antibody is administered intravenously. 
     
     
         16 . The method according to  claim 1 , wherein the antibody is administered intraperitoneally. 
     
     
         17 . The method according to  claim 1 , wherein the antibody has antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8. 
     
     
         18 . The method according to  claim 1 , wherein in the administering step, the only antibody administered is the antibody against CCR8. 
     
     
         19 . The method according to  claim 1 , wherein an Fc region of the antibody against CCR8 is free from a fucose bond with N-acetylglucosamine. 
     
     
         20 . The method according to  claim 1 , further comprising administering an anti-PD-1 antibody or an anti-PD-L1 antibody. 
     
     
         21 . The method according to  claim 1 , wherein the method further comprises administering at least one antibody selected from the group consisting of nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab.